<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Essential thrombocythemia: Treatment and prognosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Essential thrombocythemia: Treatment and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Essential thrombocythemia: Treatment and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ayalew Tefferi, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 16, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Essential thrombocythemia (ET) is a <em>BCR::ABL1</em>-negative myeloproliferative neoplasm (MPN) characterized by excessive clonal platelet production. While at least one-half of patients with ET are asymptomatic at the time of diagnosis, most will develop vasomotor, thrombotic, or hemorrhagic manifestations at some point during their disease. A small percentage of patients will progress to post-ET myelofibrosis or experience leukemic transformation. Nevertheless, ET has the most favorable prognosis among the <em>BCR::ABL1</em> MPNs.</p><p>Management and prognosis of ET are reviewed here. </p><p>Clinical manifestations, evaluation, and diagnosis of ET are presented separately. (See  <a class="medical medical_review" href="/d/html/4491.html" rel="external">"Clinical manifestations, pathogenesis, and diagnosis of essential thrombocythemia"</a>.)</p><p>Evaluation of a patient with an elevated platelet count is discussed separately. (See  <a class="medical medical_review" href="/d/html/6682.html" rel="external">"Approach to the patient with thrombocytosis"</a>.)</p><p class="headingAnchor" id="H522597045"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>The goals of current management for patients with ET are to prevent thrombosis and bleeding and alleviate symptoms; current drug therapy has not been shown to prolong survival or prevent disease progression. </p><p>ET has the most favorable prognosis among the <em>BCR::ABL1</em>-negative myeloproliferative neoplasms (MPNs; ie, ET, polycythemia vera [PV], primary myelofibrosis [PMF]). Survival for patients diagnosed with ET is approximately 20 years, but it is 33 years for patients diagnosed at &lt;60 years old [<a href="#rid1">1</a>]. Life expectancy for patients with ET is comparable to or slightly inferior to that of the general age- and sex-matched population [<a href="#rid1">1,2</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Common ET-associated symptoms and complications include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vasomotor symptoms</strong> – Vasomotor symptoms, including headache, lightheadedness, acral paresthesias, livedo reticularis, and erythromelalgia (burning pain of the hands or feet associated with erythema and warmth),  (<a class="graphic graphic_picture graphicRef81121" href="/d/graphic/81121.html" rel="external">picture 1</a>) are experienced by up to 40 percent of patients with ET. (See  <a class="medical medical_review" href="/d/html/4491.html" rel="external">"Clinical manifestations, pathogenesis, and diagnosis of essential thrombocythemia", section on 'Vasomotor symptoms'</a>.)</p><p></p><p class="bulletIndent2">Treatment with low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> is effective for relieving vasomotor symptoms in most patients with ET, as discussed below. (See <a class="local">'Low-dose aspirin'</a> below.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thrombosis </strong>– Thrombosis is the major cause of morbidity and mortality in patients with ET. There is increased risk for both venous thrombosis (eg, deep vein thrombosis, pulmonary embolus, superficial thrombophlebitis) and for arterial thrombosis (eg, cerebrovascular events, angina, myocardial infarction). </p><p></p><p class="bulletIndent2">Approximately 20 percent of patients with ET present with major thrombotic events, and another 15 percent may experience recurrent thromboses [<a href="#rid3">3,4</a>]. Thrombosis is most common in patients of any age with a prior history of thrombosis and in patients &gt;60 years with <em>JAK2 </em>V617F mutation and cardiovascular risk factors. (See  <a class="medical medical_review" href="/d/html/4491.html" rel="external">"Clinical manifestations, pathogenesis, and diagnosis of essential thrombocythemia", section on 'Thrombosis and hemorrhage'</a>.)</p><p></p><p class="bulletIndent2">Assessment of thrombotic risk, control of other risk factors for thrombosis (eg, smoking, elevated cholesterol), and risk-stratified treatment are key aspects of management for individuals with ET. (See <a class="local">'Risk stratification'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bleeding</strong> – Qualitative and quantitative platelet alterations contribute to bleeding in patients with ET. </p><p></p><p class="bulletIndent2">Some patients with platelet counts &gt;1,000,000/microL have excessive bleeding due to acquired von Willebrand syndrome (aVWS). Evaluation for aVWS is discussed below. (See <a class="local">'Laboratory studies'</a> below.)</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> should be used with caution in patients with aVWS, as discussed below. (See <a class="local">'Acquired von Willebrand syndrome'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Disease transformation</strong> – Transformation of ET to secondary myelofibrosis or acute myeloid leukemia occurs in &lt;5 percent of patients after 10 to 20 years of disease. ET is the least likely of the <em>BCR::ABL1</em>-negative MPNs to undergo disease transformation. </p><p></p><p class="bulletIndent2">Suspicion for disease transformation, diagnosis, and management are discussed below. (See <a class="local">'Disease transformation'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pregnancy loss</strong> – Patients with ET have an increased risk for complications of pregnancy (eg, thrombosis, hypertension, fetal loss). Management of pregnant patients with ET is discussed below. (See <a class="local">'Pregnancy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Current treatments effectively control symptoms and reduce complications, but they have not been shown to extend survival, cure ET, or prevent disease transformation to post-ET myelofibrosis or leukemia. </p><p></p><p class="bulletIndent1">Management of ET is stratified according to the risk for thrombotic complications. (See <a class="local">'Risk stratification'</a> below.)</p><p></p><p class="headingAnchor" id="H2753684954"><span class="h1">PRETREATMENT EVALUATION</span><span class="headingEndMark"> — </span>History and physical examination document ET-associated findings. Laboratory studies are used to assess hematologic findings and organ dysfunction that may influence management.</p><p class="headingAnchor" id="H477119058"><span class="h2">Clinical</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>History</strong> – History should evaluate the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Presence and severity of vasomotor symptoms, which may include headaches, dizziness, visual disturbances, burning dysesthesia of the palms and soles (erythromelalgia), paresthesias, acrocyanosis, and cutaneous ulcers. (See  <a class="medical medical_review" href="/d/html/4491.html" rel="external">"Clinical manifestations, pathogenesis, and diagnosis of essential thrombocythemia", section on 'Vasomotor symptoms'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prior venous thrombosis (eg, deep venous thrombosis, pelvic, mesenteric, hepatic, portal), arterial thrombosis (eg, cerebral, coronary, ophthalmic, or distal/extremities), first trimester spontaneous abortion, and history of hemorrhagic complications (eg, gastrointestinal, mucosal bleeding, epistaxis, urogenital, deep hematoma, hemarthrosis). (See  <a class="medical medical_review" href="/d/html/4491.html" rel="external">"Clinical manifestations, pathogenesis, and diagnosis of essential thrombocythemia", section on 'Thrombosis and hemorrhage'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiovascular risk factors, including hypertension, diabetes mellitus, active tobacco use, and hyperlipidemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical examination</strong> – The patient is evaluated for spleen and liver size and evidence of bleeding/bruising.</p><p></p><p class="headingAnchor" id="H260265468"><span class="h2">Laboratory studies</span><span class="headingEndMark"> — </span>Blood tests include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematology</strong> – Complete blood count with leukocyte differential and review of the peripheral blood smear. </p><p></p><p class="bulletIndent1">For patients with clinical bleeding or platelet count &gt;1000 x 10<sup>9</sup>/L (1,000,000/microL), ristocetin cofactor activity should be measured. Patients with ristocetin cofactor activity &lt;30 percent have acquired von Willebrand syndrome (aVWS). (See  <a class="medical medical_review" href="/d/html/110531.html" rel="external">"Acquired von Willebrand syndrome", section on 'Laboratory testing'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> is contraindicated in patients with aVWS because of the increased risk for severe hemorrhage. (See <a class="local">'Acquired von Willebrand syndrome'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum chemistries</strong> – Comprehensive metabolic panel, uric acid.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular studies</strong> – If not previously performed, test blood for <em>JAK2 </em>V617F mutation; if negative, test for mutations of <em>CALR </em>exon 9 and <em>MPL </em>exon 10. </p><p></p><p class="bulletIndent1">Mutations associated with ET are discussed separately. (See  <a class="medical medical_review" href="/d/html/4491.html" rel="external">"Clinical manifestations, pathogenesis, and diagnosis of essential thrombocythemia", section on 'Genetic features'</a>.)</p><p></p><p class="headingAnchor" id="H1264342901"><span class="h1">RISK STRATIFICATION</span><span class="headingEndMark"> — </span>Assessment of thrombotic risk is a key aspect of management for patients with ET. We calculate the revised International Prognostic Score for thrombosis in ET (revised IPSET-thrombosis) score to assess thrombotic risk for patients with ET [<a href="#rid5">5</a>]. The revised IPSET-thrombosis categories are: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-risk disease</strong> – History of thrombosis <strong>or</strong> age &gt;60 with <em>JAK2 </em>V617F. (See <a class="local">'High-risk ET'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intermediate-risk disease</strong> – Age &gt;60, no <em>JAK2</em> mutation, and no history of thrombosis. (See <a class="local">'Intermediate-risk ET'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-risk disease</strong> – Age ≤60, <em>JAK2</em> V617F, and no history of thrombosis. (See <a class="local">'Low-risk ET'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Very low-risk disease</strong> – Age ≤60, no <em>JAK2</em> mutation, and no history of thrombosis. (See <a class="local">'Very low-risk ET'</a> below.)</p><p></p><p class="headingAnchor" id="H2756078515"><span class="h1">HIGH-RISK ET</span><span class="headingEndMark"> — </span>Patients with a high-risk International Prognostic Score for thrombosis in ET (revised IPSET-thrombosis) score are best managed with a cytoreductive agent plus low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>. The choice of cytoreductive agent is informed by the patient’s age and potential to become pregnant.</p><p class="headingAnchor" id="H1040712400"><span class="h2">Age ≥40 years and no potential for pregnancy</span><span class="headingEndMark"> — </span>For most patients with high-risk ET, we suggest low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> plus <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>. Pegylated interferon alfa (IFNa) is a reasonable alternative for cytoreduction based on patient preference and drug tolerance.</p><p>Low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> should be used carefully, and sometimes not at all, in patients with clinically significant acquired von Willebrand syndrome (aVWS), as discussed below. (See <a class="local">'Acquired von Willebrand syndrome'</a> below.)</p><p><a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">Hydroxyurea</a>, IFNa, and <a class="drug drug_general" data-topicid="8593" href="/d/drug information/8593.html" rel="external">anagrelide</a> have comparable efficacy for ameliorating symptoms, controlling platelet counts, and lessening thrombotic risk, but hydroxyurea is associated with less toxicity. Some patients may favor IFNa because it more effectively reduces the size of the malignant clone, but this has not been proven to be associated with longer survival. </p><p>Administration of <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> is discussed below. (See <a class="local">'Hydroxyurea'</a> below.) </p><p>Treatment for patients with limited life expectancy is discussed below. (See <a class="local">'Frail or limited lifespan'</a> below.)</p><p>The choice of <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> for patients with high-risk ET is based on randomized clinical trials:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydroxyurea</strong><strong> versus no cytoreductive agent</strong> – In a phase 3 trial of patients with high-risk ET, compared with no cytoreductive treatment, <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> reduced arterial and venous thrombotic events [<a href="#rid6">6</a>]. The 114 patients were randomly assigned to hydroxyurea versus no hydroxyurea, and with a median follow-up of 27 months, there were fewer thrombotic events in those who received hydroxyurea (4 versus 24 percent). The untreated patients had platelet counts from 892,000/microL to 986,000/microL at six months, compared with &lt;600,000 platelets/microL in all patients treated with hydroxyurea. Multivariate analysis indicated that use of antiplatelet agents (only three patients were taking <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and two were taking <a class="drug drug_general" data-topicid="9996" href="/d/drug information/9996.html" rel="external">ticlopidine</a>) had no effect on thrombosis or bleeding. Hydroxyurea was not associated with cytopenias or other serious adverse effects (AEs).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydroxyurea</strong><strong> versus interferon alfa</strong> – A phase 3 trial in 168 patients with treatment-naïve, high-risk ET or polycythemia vera (PV) reported that <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> and pegylated IFNa achieved similar rates of complete response (CR), but IFNa was associated with greater toxicity [<a href="#rid7">7</a>]. Among patients with ET, CR rates at 12 months were similar for hydroxyurea (45 percent in 42 patients) and IFNa (44 percent in 39 patients); platelet control at 12 months was also similar (45 and 46 percent, respectively). CR rates also did not differ after 24 and 36 months (25 and 17 percent with hydroxyurea, respectively; 38 and 33 percent with IFNa). Thrombohemorrhagic complications did not differ between treatments. The two agents reduced <em>JAK2</em> V617F variant allele frequency (VAF) comparably; however, with IFNa, <em>JAK2</em> V617F VAF decreased consistently through month 24 while it increased after month 12 with hydroxyurea. Grade ≥3 AEs were significantly more frequent with IFNa than with hydroxyurea (46 versus 28 percent). Mucositis and anorexia were more common with hydroxyurea, while hypertension, leukopenia, flu-like symptoms, fatigue, and depression were more common with IFNa.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydroxyurea</strong><strong> versus </strong><strong>anagrelide</strong> – Both <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> and <a class="drug drug_general" data-topicid="8593" href="/d/drug information/8593.html" rel="external">anagrelide</a> were effective for controlling thromboses, but their effects and toxicity differed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A phase 3 trial that compared <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> with <a class="drug drug_general" data-topicid="8593" href="/d/drug information/8593.html" rel="external">anagrelide</a> reported that hydroxyurea more effectively reduced arterial thrombosis, bleeding, and fibrotic progression, while anagrelide was more effective for preventing venous thrombosis [<a href="#rid8">8</a>]. The trial included 809 patients with high-risk ET; the primary end point was a composite of death from thrombosis or hemorrhage, arterial or venous thrombosis, and serious hemorrhage. Long-term control of platelet counts was similar with both drugs. After five years, anagrelide was associated with a higher rate of the composite end point (16 versus 11 percent; odds ratio [OR] 1.57 [95% CI 1.04-2.37]); patients taking anagrelide also had more arterial thromboses (OR 2.16 [95% CI 1.27-3.69]), transient ischemic attacks (OR 5.72 [95% CI 2.08-15.73]), serious hemorrhage (OR 2.61 [95% 1.27-5.33]), transformation to myelofibrosis (OR 2.92 [95% CI 1.24-6.86]), and a trend toward more myocardial infarctions, unstable angina, and thrombotic stroke. However, patients treated with anagrelide had a lower risk for venous thromboses (OR 0.27 [95% 0.11-0.71]) and deep vein thrombosis (OR 0.20 [95% 0.06-0.71]). Treatment withdrawal for AEs was more frequent with anagrelide (88 versus 43 patients), but those treated with hydroxyurea had more leg ulcers and mouth ulcers.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There was no difference in thrombohemorrhagic complications among 259 patients with high-risk ET who were randomly assigned to <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> versus <a class="drug drug_general" data-topicid="8593" href="/d/drug information/8593.html" rel="external">anagrelide</a> in the ANAHYDRET trial [<a href="#rid9">9</a>]. There was no significant difference between trial arms in major arterial or venous thrombosis, severe bleeding, or rates of treatment discontinuation. Hydroxyurea was associated with more infectious events, leukopenia, and anemia, while anagrelide was associated with more cardiac events (eg, hypertension, palpitations, tachycardia). Conclusions from this study are limited because there was a high rate of discontinuation and crossover between drugs, only one-third of patients received <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, and duration of follow-up was limited.</p><p></p><p class="headingAnchor" id="H404042425"><span class="h2">Age &lt;40 years or potential for pregnancy</span><span class="headingEndMark"> — </span>For cytoreduction in younger patients (eg, &lt;40 years) and in those with potential to become pregnant, we suggest low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> plus IFNa based on efficacy and safety of IFNa in this setting. <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">Hydroxyurea</a> and <a class="drug drug_general" data-topicid="8593" href="/d/drug information/8593.html" rel="external">anagrelide</a> are contraindicated in pregnant patients. </p><p><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> should be used carefully, or not at all, in patients with clinically significant aVWS. (See <a class="local">'Acquired von Willebrand syndrome'</a> below.)</p><p>IFNa effectively controls vasomotor symptoms, platelet counts, and thrombohemorrhagic complications, but it may cause mild to moderate AEs. IFNa treatment is associated with reduction in the size of the malignant clone in patients with ET, but this molecular effect does not predict longer survival or less transformation to secondary myelofibrosis or acute myeloid leukemia (AML). Outcomes of a phase 3 trial that included IFNa are described above. (See <a class="local">'Age ≥40 years and no potential for pregnancy'</a> above.)</p><p>Administration of IFNa is discussed below. (See <a class="local">'Interferon alfa'</a> below.)</p><p>IFNa can be used safely in pregnant patients. (See <a class="local">'Pregnancy'</a> below.)</p><p class="headingAnchor" id="H1483283713"><span class="h2">Prior thrombotic events</span><span class="headingEndMark"> — </span>Management of patients with a previous thrombotic event is influenced by the type of prior thrombosis.</p><p class="headingAnchor" id="H3983402376"><span class="h3">History of arterial thrombosis</span><span class="headingEndMark"> — </span>For patients with ET and a prior arterial thrombosis, we suggest twice-daily <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> plus a cytoreductive agent. </p><p>Selection of a cytoreductive agent is discussed above. (See <a class="local">'High-risk ET'</a> above.)</p><p><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> should be used carefully, or not at all, in patients with clinically significant aVWS. (See <a class="local">'Acquired von Willebrand syndrome'</a> below.)</p><p>A retrospective analysis of 300 patients (&lt;60 years) with ET who had cardiovascular (CV) risk factors but no prior arterial events (ie, low-risk and very low-risk ET) reported that <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> reduced the risk for subsequent arterial thrombotic events [<a href="#rid10">10</a>]. Compared with low-dose aspirin, observation was associated with an increased risk for arterial thrombosis (relative risk [RR] 2.5 [95% CI 1.02-6.1]). </p><p>No studies have directly compared <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> dosing schedules for prevention of arterial events in patients with ET. The suggestion for twice-daily dosing of low-dose aspirin is based on more effective inhibition of cyclooxygenase 1 (COX-1) using divided doses [<a href="#rid11">11</a>], as described below. (See <a class="local">'Low-dose aspirin'</a> below.)</p><p class="headingAnchor" id="H3555708766"><span class="h3">History of venous thrombosis</span><span class="headingEndMark"> — </span>Patients with ET and a prior venous thrombosis should be treated with a cytoreductive agent plus systemic anticoagulation. </p><p>Selection of a cytoreductive agent is discussed above. (See <a class="local">'High-risk ET'</a> above.)</p><p>Some experts also add low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> for patients with previous venous thrombosis and mutated <em>JAK2</em> or CV risk factors. This decision should be individualized, based on joint decision-making about the balance of risks and benefits. Aspirin should be used carefully, or not at all, in patients with aVWS. (See <a class="local">'Acquired von Willebrand syndrome'</a> below.)</p><p>Systemic anticoagulation for treatment of venous thrombosis and prophylaxis are discussed separately. (See  <a class="medical medical_review" href="/d/html/95395.html" rel="external">"Venous thromboembolism: Anticoagulation after initial management"</a> and  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer"</a>.)</p><p class="headingAnchor" id="H661820901"><span class="h2">Resistance or intolerance to cytoreductive agent</span><span class="headingEndMark"> — </span>For patients with refractory disease or intolerance to the initial cytoreductive agent, we suggest changing to an alternate cytoreductive agent.</p><p>The preferred agent depends on prior treatments, comorbid conditions, toxicity, and patient preference. The most common options are <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>, IFNa, and <a class="drug drug_general" data-topicid="8593" href="/d/drug information/8593.html" rel="external">anagrelide</a>. (See <a class="local">'Treatments'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment resistance</strong> – We consider that ET is refractory to initial cytoreductive therapy based on any of the following conditions [<a href="#rid12">12</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Platelet count &gt;600,000/microL with maximal tolerated dose of the cytoreductive agent</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Platelet count &gt;400,000/microL with white blood cell (WBC) count &lt;2500/microL or hemoglobin &lt;10 g/dL </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Persistent, severe vasomotor symptoms despite platelet count &lt;400,000/microL </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence</strong> – Up to one-quarter of patients with ET who are treated with <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> demonstrate resistance or intolerance. In a study of hydroxyurea for treatment in 166 patients, resistance occurred in 15 patients and intolerance in 21 patients [<a href="#rid13">13</a>]. Patients with resistance to hydroxyurea had a median survival of 2.4 years from onset of resistance; hydroxyurea resistance was associated with sixfold higher risk of death from any cause and eightfold higher rate of developing myelofibrosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – Studies that reported outcomes of treatment of hydroxyurea-refractory ET include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A multicenter study that included 65 patients who were treated with pegylated IFNa for hydroxyurea-resistant ET reported a 69 percent overall response rate (including a 26 percent CR) at 12 months [<a href="#rid14">14</a>]. Grade ≥3 AEs included cytopenias, myalgia/arthralgia, depression, dyspnea, and headache (all in &lt;10 percent of patients); toxicity led to treatment discontinuation in 14 percent of patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A phase 2 study that randomly assigned 110 patients with <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> resistance/intolerance to <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a> versus physician's choice of best available therapy (BAT; primarily <a class="drug drug_general" data-topicid="8593" href="/d/drug information/8593.html" rel="external">anagrelide</a>, interferon, or resumption of hydroxyurea) reported comparable response rates and no difference in thrombohemorrhagic complications or leukemic progression at two years [<a href="#rid15">15</a>]. Ruxolitinib was superior by some measures of symptom relief but was associated with higher rates of AEs, including anemia, thrombocytopenia, and infections. Conclusions from this study are limited because of its nonstandardized diagnostic processes, substantial switching between BAT agents, and frequent use of hydroxyurea in patients who were previously found to be intolerant or resistant.</p><p></p><p class="headingAnchor" id="H3309191770"><span class="h1">INTERMEDIATE-RISK ET</span><span class="headingEndMark"> — </span>For patients with intermediate-risk ET, we suggest either low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> alone or low-dose aspirin plus <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>. </p><p>Management should be individualized, with consideration of cardiovascular (CV) risk factors, bleeding history, and patient preference. For patients with clinically significant acquired von Willebrand syndrome, we favor <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> alone. (See <a class="local">'Hydroxyurea'</a> below.)</p><p>Administration of low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> is discussed below. (See <a class="local">'Low-dose aspirin'</a> below.)</p><p>No randomized trials have directly evaluated the effect of adding a cytoreductive agent to low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> in patients with intermediate-risk ET. In the retrospective study that led to the development of the International Prognostic Score for thrombosis in ET (IPSET-thrombosis) score, the risk for thrombosis in intermediate-risk patients was 2.35 percent/year, which is distinct from the risk for patients with a high-risk score (3.56 percent/year) and a low-risk score (1.03 percent/year) [<a href="#rid16">16</a>]. In a subsequent analysis of this patient population, the presence of CV risk factors was not significantly associated with increased thrombotic risk [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H4265092285"><span class="h1">LOW-RISK ET</span><span class="headingEndMark"> — </span>Low-risk ET includes patients ≤60 years with <em>JAK2</em> V617F mutation but no history of thrombosis. (See <a class="local">'Risk stratification'</a> above.)</p><p class="headingAnchor" id="H674690789"><span class="h2">Initial treatment</span><span class="headingEndMark"> — </span>For initial treatment of low-risk ET, we suggest low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> rather than cytoreductive therapy. This approach is considered standard therapy for patients with low-risk disease because of the favorable prognosis and to avoid potential adverse effects (AEs) of cytoreductive agents.</p><p><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> should be used carefully, or not at all, in patients with clinically significant acquired von Willebrand syndrome, as discussed below. (See <a class="local">'Acquired von Willebrand syndrome'</a> below.) </p><p>Studies of initial treatment of patients with low-risk ET or very low-risk ET include:</p><p class="bulletIndent1"><span class="glyph">●</span>In a phase 3 trial of patients with low-risk ET, there was no difference in outcomes when <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> was added to low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, compared with low-dose aspirin alone [<a href="#rid17">17</a>]. The trial randomly assigned these treatments to 382 patients (40 to 59 years) who had no history of ischemia, thrombosis, embolism, hemorrhage, platelets ≥1,500 x 10<sup>9</sup>/L, hypertension, or diabetes. With a median follow-up of 73 months, hydroxyurea did not affect overall survival; disease transformation; or a composite endpoint of arterial or venous thrombosis, serious hemorrhage, or death from vascular cause. The incidence of significant vascular events in the entire cohort of enrolled patients was &lt;1 per 100 patient-years. There was no difference in AEs between trial arms. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> was associated with fewer venous thromboses than observation alone in patients with low-risk ET in a retrospective analysis of 300 patients; however, the analysis also included patients with very low-risk ET, and there was no benefit of aspirin across the entire study population [<a href="#rid10">10</a>]. For patients &lt;60 years with<em> JAK2</em>-mutated ET, compared with those taking aspirin, observation was associated with a higher risk for venous thrombosis (relative risk [RR] 4.0 [95% CI 1.2-12.9]). For patients with low-risk ET and cardiovascular risk factors, compared with low-dose aspirin, observation was associated with an increased risk for arterial thrombosis (RR 2.5 [95% CI 1.02-6.1]). Patients with platelets &gt;1000 x<sup> </sup>10<sup>9</sup>/L had an increased risk of major bleeding (RR 5.4 [95% CI 1.7-17.2]). </p><p></p><p class="headingAnchor" id="H2134213239"><span class="h2">Persistent symptoms in low-risk patients</span><span class="headingEndMark"> — </span>For patients with inadequate control of vasomotor symptoms while taking a single dose of low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, we suggest twice-daily low-dose aspirin, using no more than 100 mg <strong>total</strong> per day. </p><p>It is important to use ≤100 mg total daily <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> dose (eg, aspirin 42 mg twice daily by mouth) to avoid excessive bleeding that may be exacerbated by ET-associated platelet function abnormalities. </p><p>There is no proof that divided dosing is more effective for controlling vasomotor symptoms than a single daily dose, but some individuals have better symptom control with twice-daily dosing. Additionally, there is biochemical evidence that divided doses are more effective for suppressing platelet cyclooxygenase 1 (COX-1) activity (the target of action), as described below. (See <a class="local">'Low-dose aspirin'</a> below.)</p><p class="bulletIndent1">For symptoms that persist despite twice-daily low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, we suggest adding cytoreductive therapy, as described for patients with high-risk ET. (See <a class="local">'High-risk ET'</a> above.)</p><p></p><p class="headingAnchor" id="H2528283780"><span class="h1">VERY LOW-RISK ET</span><span class="headingEndMark"> — </span>For patients with very low-risk ET, we suggest either observation or low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> alone.</p><p>Management of patients with very low-risk ET should be individualized, with consideration of the degree of vasomotor symptoms, cardiovascular (CV) risk factors, risk of bleeding, and patient preference. The risk of thrombosis in these patients is very low, and survival is comparable to that of the general population [<a href="#rid2">2</a>]. </p><p><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> should be used carefully, or not at all, in patients with clinically significant acquired von Willebrand syndrome. (See <a class="local">'Acquired von Willebrand syndrome'</a> below.)</p><p><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> did not reduce the risk of thrombosis in patients with very low-risk ET in a retrospective analysis of 300 patients with ET [<a href="#rid10">10</a>]. By contrast, aspirin was associated with improved outcomes for patients with low-risk ET (ie, those who had either <em>JAK2</em> V617F or CV risk factors), as described above. (See <a class="local">'Initial treatment'</a> above.) </p><p>Patients with very low-risk ET who develop vasomotor symptoms should be managed as discussed above. (See <a class="local">'Low-risk ET'</a> above.)</p><p class="headingAnchor" id="H1701433822"><span class="h1">TREATMENTS</span><span class="headingEndMark"> — </span>Treatments for ET are used to alleviate vasomotor symptoms, control splenomegaly, and reduce thrombohemorrhagic complications. No treatment has been proven to reduce transformation to secondary myelofibrosis or leukemic progression.</p><p class="headingAnchor" id="H2453357220"><span class="h2">Low-dose aspirin</span><span class="headingEndMark"> — </span>Low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> can reduce vasomotor symptoms and thrombohemorrhagic complications in most patients with ET. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> refers to doses of 40 to 100 mg per day. It can be taken once or twice daily, but the total daily dose should be ≤100 mg. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> should be used carefully, or not at all, in patients with clinically significant acquired von Willebrand syndrome. (See <a class="local">'Acquired von Willebrand syndrome'</a> below.)</p><p></p><p class="bulletIndent1">There is no persuasive evidence that twice-daily dosing more effectively controls vasomotor symptoms or reduces thrombotic risk. However, twice-daily low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> was more effective than single-daily dosing for inhibiting cyclooxygenase 1 (COX-1; the target of action for aspirin) in a randomized trial of 245 patients with ET [<a href="#rid11">11</a>]. This effect may be due to accelerated turnover of platelet COX-1 in patients with ET [<a href="#rid18">18,19</a>]. Some patients with persistent vasomotor symptoms while taking single-daily low-dose aspirin respond better to twice-daily low-dose aspirin. </p><p></p><p class="bulletIndent1">Higher-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (eg, 900 mg/day) is discouraged because of increased gastrointestinal bleeding when high-dose aspirin was used in combination with <a class="drug drug_general" data-topicid="9377" href="/d/drug information/9377.html" rel="external">dipyridamole</a> in patients with polycythemia vera (PV) [<a href="#rid20">20,21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – Low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> is well-tolerated and has no major adverse effects (AEs).</p><p></p><p class="bulletIndent1">There was no increase in major bleeding episodes in patients taking low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> compared with no aspirin in a randomized trial of patients with ET [<a href="#rid22">22</a>].</p><p></p><p>Management of aspirin-resistant symptoms in patients with low-risk ET or very low-risk ET is discussed above. (See <a class="local">'Persistent symptoms in low-risk patients'</a> above.)</p><p class="headingAnchor" id="H442886485"><span class="h2">Hydroxyurea</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">Hydroxyurea</a> is an oral agent that effectively reduces platelet counts, controls vasomotor symptoms and splenomegaly, and reduces thromboses in patients with ET. Hydroxyurea inhibits deoxyribonucleic acid (DNA) synthesis by acting on ribonucleotide reductase.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – The initial dose of <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> is 15 mg/kg per day by mouth. We generally begin treatment with either one or two 500 mg tablets daily. Patients should be advised to avoid missing doses.</p><p></p><p class="bulletIndent1">The dose of <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> should be reduced by 50 percent in patients with creatinine clearance &lt;60 mL/min. Because the effect of hydroxyurea may resemble that of <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> deficiency, folic acid supplementation should be considered (to avoid masked folate deficiency); folic acid does not reverse the effects of hydroxyurea on symptoms or blood counts.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">Hydroxyurea</a> is contraindicated in pregnant individuals, and it should be avoided in patients who are breastfeeding or with childbearing potential. (See <a class="local">'Pregnancy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response monitoring</strong> – The dose of <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> is adjusted to achieve a target platelet count of 100,000/microL to 400,000/microL while limiting neutropenia and anemia [<a href="#rid3">3,23</a>].</p><p></p><p class="bulletIndent1">Complete blood counts are initially obtained weekly, but the frequency may be reduced as blood counts stabilize. Treatment is accompanied by varying degrees of neutropenia and anemia with megaloblastic features (eg, increased mean cell volume). </p><p></p><p class="bulletIndent1">Liver function tests should be obtained periodically to monitor for hydroxyurea-induced alterations in liver function. </p><p></p><p class="bulletIndent1">The onset of action is rapid, and blood counts generally decline within three to five days of beginning treatment; similarly, the effect of <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> is short-lived when it is stopped. Dose adjustments should not be made more than once per week to prevent wide fluctuations in the platelet count. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">Hydroxyurea</a> is well-tolerated. AEs include oral ulcers, hyperpigmentation, skin rash, and nail changes but are usually mild  (<a class="graphic graphic_table graphicRef63410" href="/d/graphic/63410.html" rel="external">table 1</a>) [<a href="#rid24">24</a>]. Some patients experience fever, nausea, diarrhea, abnormal liver function tests, or alopecia; rare cases of severe (including fatal) pulmonary toxicity have been reported [<a href="#rid13">13,24,25</a>].</p><p></p><p class="bulletIndent1">In a study of 993 patients treated with <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> for myeloproliferative neoplasms (one-half with ET), mucocutaneous toxicity (eg, erythema, perimalleolar or oral aphthous ulcers) was reported in 8 percent; one-half of affected patients required permanent drug discontinuation [<a href="#rid26">26</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – Response rates to <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> have varied among studies because of different diagnostic criteria and target platelet levels. Among 166 patients treated with hydroxyurea with a target platelet count &lt;400,000/microL, the complete response rate was 81 percent and partial response rate was 15 percent, using the European LeukemiaNet (ELN) and International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent1">Randomized trials in ET that included <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> are described above. (See <a class="local">'Age ≥40 years and no potential for pregnancy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Leukemogenesis</strong> – There is no persuasive evidence that <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> is associated with increased risk for leukemia in patients with ET. Other treatments that are now rarely used (eg, <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a>, <sup>32</sup>P) are clearly associated with increased rates of malignant transformation.</p><p></p><p class="bulletIndent1">The incidence of myelodysplastic syndromes/neoplasms (MDS) and acute myeloid leukemia (AML) in patients with ET has generally been estimated to be 0 to 5 percent in most long-term studies [<a href="#rid2">2,8,27-35</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among 357 patients followed for a median of eight years, the incidence of MDS or AML was 4.5 percent [<a href="#rid27">27</a>]. This risk was 3.5 percent in patients treated with <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> alone but 14 percent in patients receiving hydroxyurea in combination with <sup>32</sup>P, <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a>, or pipobroman. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A retrospective study of 435 patients with ET reported a 2 percent cumulative incidence of AML after 15 years; the risk for developing AML was not associated with the use of <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1">Long-term treatment with <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> has not been associated with an increased leukemia in nonhematologic conditions (eg, sickle cell disease), as discussed separately. (See  <a class="medical medical_review" href="/d/html/7071.html" rel="external">"Hydroxyurea use in sickle cell disease", section on 'Adverse effects'</a>.)</p><p></p><p class="headingAnchor" id="H2600602617"><span class="h2">Interferon alfa</span><span class="headingEndMark"> — </span>Interferon alfa (IFNa) is a pharmaceutical product obtained from human leukocytes that contains several naturally occurring subtypes of interferon alpha. Pegylated IFNa provides a more favorable toxicity profile than conventional IFNa, and its prolonged activity is compatible with once-weekly dosing [<a href="#rid37">37-39</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – The initial dose of pegylated IFNa is 45 mcg/week subcutaneously for the first two weeks. The dose is increased, as tolerated, to a maximal dose of 180 mcg/week. </p><p></p><p class="bulletIndent1">Use of mono-pegylated IFNa-2b (ropeginterferon) 100 mcg every two weeks, increased by 50 mcg every two weeks to a maximum of 500 mcg, is also acceptable.</p><p></p><p class="bulletIndent1">The dose of IFNa is titrated to maintain the platelet count between 100 x 10<sup>9</sup>/L and 400 x 10<sup>9</sup>/L. </p><p></p><p class="bulletIndent1">We favor pegylated IFNa rather than nonpegylated IFNa because of comparable efficacy, ease of administration, and the more favorable toxicity profile [<a href="#rid37">37,38,40-43</a>]. If pegylated IFNa is not available, the usual starting dose of nonpegylated IFNa is 3 million units subcutaneously three times per week.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – Treatment with pegylated IFNa in a phase 3 trial caused grade ≥3 AEs in nearly one-half of patients; the most common grade ≥3 AEs were fatigue (7 percent), hypertension (7 percent), and headache (4 percent) [<a href="#rid7">7</a>]. Grade 1 to 2 AEs occurred in one-half of patients and included fatigue (49 percent), flu-like symptoms (22 percent), headache (22 percent), peripheral sensory neuropathy (20 percent), pain in extremities (20 percent), and depression (15 percent). </p><p></p><p class="bulletIndent1">Studies using nonpegylated IFNa reported treatment discontinuation in up to one-quarter of patients due to treatment-related AEs [<a href="#rid40">40,44-46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – Treatment with IFNa was associated with a hematologic response in all 31 patients with <em>CALR</em>-mutated ET and reduced <em>CALR</em> mutant allelic burden (from 41 percent at baseline to 26 percent; two patients had a complete molecular response) [<a href="#rid42">42</a>]. </p><p></p><p class="bulletIndent1">A randomized trial that compared IFNa with <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> for patients with high-risk ET is discussed above. (See <a class="local">'Age ≥40 years and no potential for pregnancy'</a> above.)</p><p></p><p class="headingAnchor" id="H3225776570"><span class="h2">Anagrelide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8593" href="/d/drug information/8593.html" rel="external">Anagrelide</a> is an oral imidazoquinoline that effectively lowers platelet counts and reduces ET-related symptoms. Anagrelide also inhibits platelet aggregation (by reducing platelet anti-cyclic AMP phosphodiesterase activity), but its effect on platelet function is only seen with doses that are higher than those used for controlling thrombocytosis [<a href="#rid47">47-49</a>]. Use of anagrelide for ET has been limited by concerns about the potential for cardiac toxicity and post-ET myelofibrosis. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – The initial dose is 0.5 mg by mouth, two to four times daily.</p><p></p><p class="bulletIndent1">The dose is titrated to maintain the platelet count between 100 x 10<sup>9</sup>/L and 400 x 10<sup>9</sup>/L. The usual maintenance dose is 1 to 4 mg/day. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8593" href="/d/drug information/8593.html" rel="external">Anagrelide</a> must be given with caution to patients with known or suspected heart disease; this may limit its use in older patients [<a href="#rid50">50</a>]. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8593" href="/d/drug information/8593.html" rel="external">Anagrelide</a> is contraindicated in patients who are pregnant or may become pregnant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – The most common AEs are headache, palpitations/tachycardia, and fluid retention; these effects are thought to be related to its vasodilatory properties. <a class="drug drug_general" data-topicid="8593" href="/d/drug information/8593.html" rel="external">Anagrelide</a> has been associated with acquired idiopathic cardiomyopathy and high output heart failure [<a href="#rid51">51</a>]. </p><p></p><p class="bulletIndent1">Treatment of 577 patients with <a class="drug drug_general" data-topicid="8593" href="/d/drug information/8593.html" rel="external">anagrelide</a> for thrombocythemia, including ET, reported 24 percent fluid retention, and 2 percent of patients had heart failure [<a href="#rid52">52</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – Randomized trials that compared <a class="drug drug_general" data-topicid="8593" href="/d/drug information/8593.html" rel="external">anagrelide</a> with <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> for prevention of thrombosis in patients with ET reported similar efficacy, but anagrelide was associated with greater toxicity. (See <a class="local">'High-risk ET'</a> above.)</p><p></p><p class="headingAnchor" id="H3849495108"><span class="h2">Alternative approaches</span><span class="headingEndMark"> — </span>Other agents can be used when <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>, IFNa, and <a class="drug drug_general" data-topicid="8593" href="/d/drug information/8593.html" rel="external">anagrelide</a> do not provide relief of ET-related symptoms or fail to control thrombocytosis without significant leukopenia.</p><p>Treatment choice for treatment resistance or intolerance are discussed below. (See <a class="local">'Resistance or intolerance to cytoreductive agent'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ruxolitinib</strong> – Response rates were comparable between <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a> versus best available therapy in hydroxyurea-unresponsive/intolerant patients with high-risk ET in a randomized phase 2 study [<a href="#rid53">53</a>]. The two study arms were associated with comparable rates of complete response at one-year and two-year rates of thrombosis, hemorrhage, and leukemic/fibrotic transformation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pipobroman</strong> – Pipobroman is an oral piperazine derivative that is classified as an alkylating agent [<a href="#rid54">54</a>]. It is used for treatment of ET in Europe, but it is not available in the United States. </p><p></p><p class="bulletIndent1">The initial dose of pipobroman is 0.8 to 1 mg/kg per day by mouth. AEs include nausea, abdominal cramps, diarrhea, stomatitis, and dry skin. </p><p></p><p class="bulletIndent1">In studies with a short-term follow-up, pipobroman was not associated with an increased risk of AML in ET, but a small risk may exist with long-term therapy [<a href="#rid27">27,55-57</a>]. The risk of developing AML increases significantly when pipobroman is used with other agents, such as <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> [<a href="#rid27">27</a>]. (See <a class="local">'Hydroxyurea'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other approaches</strong> – Historically, <sup>32</sup>P and <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a> were used to control platelet counts and reduce the risk of thrombosis in ET. However, both agents are associated with increased rates of AML, and they are not recommended except in special settings. As an example, <sup>32</sup>P may be appropriate in a patient with ET who has life-shortening comorbidities that make medication administration unusually difficult, as discussed below. (See <a class="local">'Frail or limited lifespan'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Apheresis</strong> – Apheresis can transiently reduce extreme thrombocytosis in association with acute, severe thrombotic or hemorrhagic events. However, this must be followed by treatment with a cytoreductive agent to maintain control of the platelet count.</p><p></p><p class="bulletIndent1">Apheresis is discussed separately. (See  <a class="medical medical_review" href="/d/html/7941.html" rel="external">"Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology"</a>.)</p><p></p><p class="headingAnchor" id="H2408097992"><span class="h1">RESPONSE MONITORING</span><span class="headingEndMark"> — </span>Patients are monitored to assess symptoms, splenomegaly, bleeding, thrombosis, blood counts, and disease progression. </p><p>We do not perform routine scheduled bone marrow examinations outside of a clinical trial. However, we perform a bone marrow examination if there is an unexpected change in blood counts or other evidence of disease transformation.</p><p>The frequency of visits is influenced by the presence and severity of symptoms and disease complications, the type of treatment, and concerns of the patient or clinician.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low risk or very low risk</strong> – Patients who are observed or treated with low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> may require only annual or semiannual visits.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High risk</strong> <strong>or intermediate risk</strong> – Patients treated with cytoreductive therapy and/or systemic anticoagulation are seen based on the treatment response and stability of blood counts and anticoagulation.</p><p></p><p>The European LeukemiaNet (ELN) and International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) published criteria for monitoring symptoms, spleen and liver size, platelet count, leukocyte count, bone marrow histology, hemorrhagic or thrombotic events, and transformation to leukemia or post-ET myelofibrosis [<a href="#rid58">58,59</a>].</p><p class="headingAnchor" id="H3865222363"><span class="h1">SPECIAL POPULATIONS</span><span class="headingEndMark"> — </span>Distinctive management is needed for ET in certain populations of patients. </p><p class="headingAnchor" id="H3606060889"><span class="h2">Acquired von Willebrand syndrome</span><span class="headingEndMark"> — </span>Acquired von Willebrand syndrome (aVWS) is thought to be caused by adsorption of von Willebrand factor to the expanded population of platelets or by increased proteolysis from platelet proteases. (See  <a class="medical medical_review" href="/d/html/110531.html" rel="external">"Acquired von Willebrand syndrome"</a>.) </p><p>The syndrome should be suspected in patients with ET who have bleeding and/or &gt;1000 x 10<sup>9</sup> platelets/L (&gt;1,000,000/microL). Diagnosis of aVWS is based on ristocetin cofactor activity &lt;30 percent. (See  <a class="medical medical_review" href="/d/html/110531.html" rel="external">"Acquired von Willebrand syndrome", section on 'Diagnostic evaluation'</a>.)</p><p><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> should be used carefully, or not at all, in patients with clinically significant aVWS. For patients with low-risk ET and very low-risk ET, cytoreductive therapy can be used to control vasomotor symptoms and reduce thrombotic risk, as described for patients with high-risk ET. (See <a class="local">'High-risk ET'</a> above.)</p><p>The risk of hemorrhage is significantly increased by low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> in patients with aVWS. In a retrospective study of 300 patients with low-risk ET, patients with platelets &gt;1000 x<sup> </sup>10<sup>9</sup>/L had an increased risk of major bleeding (relative risk [RR] 5.4 [95% CI 1.7-17.2]) [<a href="#rid10">10</a>]. </p><p class="headingAnchor" id="H3268490698"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>Management of ET in pregnant patients or those who desire to become pregnant is guided by the need to relieve symptoms and reduce complications while avoiding treatments that may harm the developing fetus.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk-based management</strong> – Pregnant patients with ET are treated according to the risk for thrombosis, as described above. (See <a class="local">'Risk stratification'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lower-risk ET</strong> – Patients with low-risk or very low-risk ET are generally treated with low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> to relieve ET-associated symptoms and to reduce pregnancy loss. (See <a class="local">'Low-risk ET'</a> above.)</p><p></p><p class="bulletIndent2">We do not routinely treat pregnant patients with interferon alfa (IFNa) unless there are other indications for its use. However, some experts offer IFNa for patients with ET who have had recurrent spontaneous abortions [<a href="#rid60">60-62</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Higher-risk ET</strong> – IFNa is the preferred cytoreductive agent because both <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> and <a class="drug drug_general" data-topicid="8593" href="/d/drug information/8593.html" rel="external">anagrelide</a> are contraindicated in pregnant and lactating individuals. (See <a class="local">'Age &lt;40 years or potential for pregnancy'</a> above.)</p><p></p><p class="bulletIndent2">For pregnant patients with uncontrolled thrombocytosis who cannot tolerate IFNa, a decision to use <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> or <a class="drug drug_general" data-topicid="8593" href="/d/drug information/8593.html" rel="external">anagrelide</a> should be made using joint decision-making. </p><p></p><p class="bulletIndent2">We do not consider inadvertent exposure to <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> or <a class="drug drug_general" data-topicid="8593" href="/d/drug information/8593.html" rel="external">anagrelide</a> a reason to terminate a pregnancy. Successful pregnancies have been reported after exposure to hydroxyurea in the first trimester in patients with ET and other conditions [<a href="#rid63">63</a>]. Similarly, no ill effects to the fetus were observed following exposure to hydroxyurea in the second and third trimesters [<a href="#rid60">60,62,64-66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thromboprophylaxis</strong> – We do not routinely offer thromboprophylaxis to pregnant patients unless there are other indications, such as prior venous thrombosis or cesarean delivery. </p><p></p><p class="bulletIndent1">No prospective studies have evaluated thromboprophylaxis in pregnant patients with ET. Thromboprophylaxis for pregnant patients is discussed separately. (See  <a class="medical medical_review" href="/d/html/1347.html" rel="external">"Venous thromboembolism in pregnancy: Prevention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent spontaneous abortions</strong> – Patients with ET have a higher rate of fetal loss compared with the general population. Studies evaluating the risk of spontaneous abortion in women with ET have reported mixed results, but <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and IFNa may be associated with a higher probability of live birth. </p><p></p><p class="bulletIndent1">There is no consensus for the use of <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and/or IFNa for patients with ET and recurrent spontaneous abortions.</p><p></p><p class="bulletIndent1">A meta-analysis of 1210 pregnancies in 767 patients with myeloproliferative neoplasms (most with ET) reported a 3.1 percent incidence of pre-eclampsia and a 71.3 percent rate of live births without significant maternal or fetal adverse effects (AEs; compared with 80 percent in the general population) [<a href="#rid67">67</a>]. The odds ratio (OR) for a live birth without significant maternal or fetal AEs was higher in the 227 patients taking <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (OR 8.6 [95% CI 4.0-18.1]) and in the 90 patients taking IFNa (OR 9.7 [95% CI 2.3-41.0]).</p><p></p><p class="headingAnchor" id="H3364238221"><span class="h2">Frail or limited lifespan</span><span class="headingEndMark"> — </span>In settings where comorbid illnesses are expected to limit lifespan (eg, to less than three to five years) or in situations where oral administration of medications is especially challenging (eg, severe dementia), <sup>32</sup>P can be effective for controlling the platelet count, despite concern regarding longer-term risk of leukemic transformation.</p><p class="headingAnchor" id="H1790856956"><span class="h2">Disease transformation</span><span class="headingEndMark"> — </span>ET progresses to post-ET myelofibrosis (MF) or secondary acute myeloid leukemia (AML) in a small subset of patients. </p><p>ET transformation should be suspected in patients with unexpected cytopenias, circulating blasts and other immature forms, and exacerbation of ET-associated symptoms. Bone marrow examination is required to evaluate these conditions. </p><p>Details of evaluation and diagnosis of MF and secondary AML are presented separately. (See  <a class="medical medical_review" href="/d/html/4529.html" rel="external">"Clinical manifestations and diagnosis of primary myelofibrosis"</a> and  <a class="medical medical_review" href="/d/html/4506.html" rel="external">"Therapy-related myeloid neoplasms: Epidemiology, causes, evaluation, and diagnosis"</a>.)</p><p>The risk of disease transformation in ET is considerably lower than the risk of thrombosis, as illustrated by the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 435 patients with ET, the 15-year cumulative risks of thrombosis, secondary AML, and post-ET MF were 17, 2, and 4 percent, respectively [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the IPSET study of 891 patients with ET, 15-year cumulative risks of AML and overt fibrotic progression were 2 and 9 percent, respectively [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a single-institution study of 605 patients with ET followed for a median of seven years, AML was documented in 3.3 percent [<a href="#rid28">28</a>]. Low levels of hemoglobin (&lt;12 g/dL in females, &lt;13.5 in males) and platelet count ≥1000 x 10<sup>9</sup>/L were risk factors for the development secondary AML in multivariate analysis. Patients with none, one, or both risk factors had 0.4, 4.8, and 6.5 percent incidence of AML, respectively. Risk for secondary AML was not associated with <em>JAK2 </em>V617F mutation treatment with a cytoreductive agent. </p><p></p><p>Management of post-ET MF is described separately. (See  <a class="medical medical_review" href="/d/html/4531.html" rel="external">"Myelofibrosis (MF): Management of primary MF and secondary MF"</a>.)</p><p>Management of post-ET secondary AML is discussed separately. (See  <a class="medical medical_review" href="/d/html/122864.html" rel="external">"Therapy-related myeloid neoplasms: Management and prognosis"</a>.)</p><p class="headingAnchor" id="H3923961588"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Increased age and prior thrombosis are associated with shorter survival and increased thrombotic risk in patients with ET.</p><p class="headingAnchor" id="H958690932"><span class="h2">Survival</span><span class="headingEndMark"> — </span>Most patients with ET enjoy a normal life expectancy, but survival is inferior in patients with increased age, prior thrombosis, and other factors.</p><p class="bulletIndent1"><span class="glyph">●</span>Multivariable analysis of 891 patients with ET reported that age &gt;60 years, history of thrombosis, elevated white blood cell (WBC) count, and anemia were associated with survival [<a href="#rid2">2</a>]. Overall survival (OS) at 10 years was 89 percent, and the 15-year OS was 80 percent. Hazard ratios (HRs) for death were age &gt;60 years (HR 6.7 [95% CI 4.34-10.3]), previous thrombosis (HR 2.81 [95% CI 1.95-4.06]), hemoglobin &lt;12 g/dL (HR 2.95 [95% CI 1.73-5.04]), and WBC &gt;11 x 10<sup>9</sup>/L (HR 2.01 [95% CI 1.39-2.90]). Survival of patients with ET was comparable to that of the sex- and age-standardized European population.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A single-institution study of 605 patients with ET also identified age ≥60 years, prior venous thrombosis, leukocytosis (≥15,000 WBC/microL), and anemia (&lt;12 g/dL in females; &lt;13.5 g/dL in males) as being independently associated with inferior survival [<a href="#rid28">28</a>]. </p><p></p><p class="headingAnchor" id="H691041758"><span class="h2">Thrombosis</span><span class="headingEndMark"> — </span>Prior thrombosis, age &gt;60 years, <em>JAK2 </em>V617F mutation, and cardiovascular (CV) risk factors (hypertension, diabetes, active tobacco use) are associated with increased thrombotic risk in patients with ET. </p><p>The revised International Prognostic Score for thrombosis in ET (IPSET)-thrombosis model was derived from a cohort of 891 subjects with ET [<a href="#rid16">16</a>]. This study reported the following associations with thrombosis: age &gt;60 years (HR 1.50), history of thrombosis (HR 1.93), CV risk factors (HR 1.56), and <em>JAK2</em> V617F (HR 2.04). </p><p>Similar findings were reported in other studies [<a href="#rid36">36,68-70</a>]. </p><p>Use of the revised IPSET-thrombosis model is discussed above. (See <a class="local">'Risk stratification'</a> above.)</p><p class="headingAnchor" id="H476805700"><span class="h2">Disease transformation</span><span class="headingEndMark"> — </span>The risk of leukemic transformation to acute myeloid leukemia (AML) or post-ET myelofibrosis (MF) is considerably lower than the risk of thrombosis in ET, as illustrated by the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 435 patients with ET, the 15-year cumulative risks of thrombosis, AML, and post-ET MF were 17, 2, and 4 percent, respectively [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the IPSET study of 891 patients with ET, 15-year cumulative risks of AML and overt fibrotic progression were 2 and 9 percent, respectively [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a single-institution study of 605 patients with ET followed for a median of seven years, AML was reported in 3.3 percent [<a href="#rid28">28</a>]. Multivariate analysis revealed low hemoglobin levels, and platelet count ≥1,000,000/microL were identified as risk factors for AML, while <em>JAK2 </em>V617F and cytoreductive therapy were not associated with risk for AML.</p><p></p><p class="headingAnchor" id="H3641517235"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116776.html" rel="external">"Society guideline links: Myeloproliferative neoplasms"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Essential thrombocythemia (ET) is a <em>BCR::ABL1</em>-negative myeloproliferative neoplasm characterized by excessive clonal platelet production. ET may be asymptomatic at presentation or may manifest vasomotor symptoms (eg, erythromelalgia, acrocyanosis, headaches, cutaneous ulcers), thrombosis, or bleeding. </p><p></p><p class="bulletIndent1">Diagnosis of ET is discussed separately. (See  <a class="medical medical_review" href="/d/html/4491.html" rel="external">"Clinical manifestations, pathogenesis, and diagnosis of essential thrombocythemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment evaluation </strong>– Evaluate vasomotor findings, organomegaly, thrombosis, bleeding, and blood counts. (See <a class="local">'Pretreatment evaluation'</a> above.)</p><p></p><p class="bulletIndent1">Patients with bleeding or platelets &gt;1000 x<sup> </sup>10<sup>9</sup>/L (&gt;1,000,000/microL) should be tested for acquired von Willebrand syndrome (aVWS). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk stratification</strong>. (See <a class="local">'Risk stratification'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High risk</p><p class="bulletIndent2"><span class="glyph">•</span>Intermediate risk</p><p class="bulletIndent2"><span class="glyph">•</span>Low risk</p><p class="bulletIndent2"><span class="glyph">•</span>Very low risk</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High risk </strong>– Treatment includes a cytoreductive agent <strong>plus</strong> low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, but aspirin should be used with caution in patients with aVWS. (See <a class="local">'High-risk ET'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choice of cytoreductive agent</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Age ≥40 years and not pregnant</strong> – For most patients with high-risk ET, we suggest <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> plus <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> rather other cytoreductive agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Age ≥40 years and no potential for pregnancy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Age &lt;40 years and/or potential for pregnancy</strong> – We suggest <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> plus interferon alfa (IFNa) rather than aspirin alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>); <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> and <a class="drug drug_general" data-topicid="8593" href="/d/drug information/8593.html" rel="external">anagrelide</a> are contraindicated in pregnancy. (See <a class="local">'Age &lt;40 years or potential for pregnancy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with prior thrombosis</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Prior arterial thrombosis</strong> – We suggest adding twice-daily low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> to cytoreduction (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'History of arterial thrombosis'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Prior venous thrombosis</strong> – Systemic anticoagulation is added to cytoreduction. (See <a class="local">'History of venous thrombosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Resistance/intolerance to initial therapy</strong> – For resistance or intolerance to <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>, we suggest changing to IFNa (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Parameters for defining resistance are discussed above. (See <a class="local">'Resistance or intolerance to cytoreductive agent'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intermediate-risk ET</strong> – In most patients, we suggest either low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> alone or low-dose aspirin plus <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Intermediate-risk ET'</a> above.)</p><p></p><p class="bulletIndent1">However, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> should be used with caution in patients with aVWS. (See <a class="local">'Acquired von Willebrand syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-risk ET</strong>. (See <a class="local">'Low-risk ET'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial therapy</strong> – In most patients, we suggest low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> rather than cytoreduction (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Low-risk ET'</a> above.)</p><p></p><p class="bulletIndent2">However, for patients with aVWS, we favor cytoreductive therapy rather than <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>. (See <a class="local">'Acquired von Willebrand syndrome'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Persistent symptoms</strong> – For inadequate symptom control, we suggest twice-daily low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (≤100 mg <strong>total</strong> per day) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Persistent symptoms in low-risk patients'</a> above.)</p><p></p><p class="bulletIndent2">Add cytoreduction if symptoms persist with twice-daily low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Very low-risk ET</strong> – We suggest either observation or low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> rather than cytoreduction (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Very low-risk ET'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response monitoring</strong> – Assess symptoms, bleeding, thrombosis, and platelet count. (See <a class="local">'Response monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Special populations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acquired von Willebrand syndrome</strong> – We weigh the risk of bleeding with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> against the degree of symptoms in patients with aVWS. (See <a class="local">'Acquired von Willebrand syndrome'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pregnancy </strong>– Low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and pegylated IFNa can be used safely in pregnancy. (See <a class="local">'Pregnancy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Frail or limited lifespan</strong> – Options include <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>, <a class="drug drug_general" data-topicid="8593" href="/d/drug information/8593.html" rel="external">anagrelide</a>, <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a>, or <sup>32</sup>P. (See <a class="local">'Frail or limited lifespan'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Disease transformation</strong> – Evaluate bone marrow for unexpected changes in blood counts or abnormal circulating cells that suggest disease transformation. (See <a class="local">'Disease transformation'</a> above.)</p><p></p><p class="headingAnchor" id="H1104152985"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editors of UpToDate acknowledge the contributions of Stanley L Schrier, MD as Section Editor on<strong> </strong>this topic, his tenure as the founding Editor-in-Chief for UpToDate in Hematology, and his dedicated and longstanding involvement with the UpToDate program.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014; 124:2507.</a></li><li><a class="nounderline abstract_t">Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011; 29:3179.</a></li><li><a class="nounderline abstract_t">Fenaux P, Simon M, Caulier MT, et al. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66:549.</a></li><li><a class="nounderline abstract_t">Randi ML, Fabris F, Cella G, et al. Cerebral vascular accidents in young patients with essential thrombocythemia: relation with other known cardiovascular risk factors. Angiology 1998; 49:477.</a></li><li><a class="nounderline abstract_t">Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J 2015; 5:e369.</a></li><li><a class="nounderline abstract_t">Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332:1132.</a></li><li><a class="nounderline abstract_t">Mascarenhas J, Kosiorek HE, Prchal JT, et al. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood 2022; 139:2931.</a></li><li><a class="nounderline abstract_t">Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353:33.</a></li><li><a class="nounderline abstract_t">Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 2013; 121:1720.</a></li><li><a class="nounderline abstract_t">Alvarez-Larrán A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 2010; 116:1205.</a></li><li><a class="nounderline abstract_t">Rocca B, Tosetto A, Betti S, et al. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood 2020; 136:171.</a></li><li><a class="nounderline abstract_t">Barosi G, Besses C, Birgegard G, et al. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia 2007; 21:277.</a></li><li><a class="nounderline abstract_t">Hernández-Boluda JC, Alvarez-Larrán A, Gómez M, et al. Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. Br J Haematol 2011; 152:81.</a></li><li><a class="nounderline abstract_t">Yacoub A, Mascarenhas J, Kosiorek H, et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood 2019; 134:1498.</a></li><li><a class="nounderline abstract_t">Harrison CN, Mead AJ, Panchal A, et al. Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial. Blood 2017.</a></li><li><a class="nounderline abstract_t">Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012; 120:5128.</a></li><li><a class="nounderline abstract_t">Godfrey AL, Campbell PJ, MacLean C, et al. Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. J Clin Oncol 2018; 36:3361.</a></li><li><a class="nounderline abstract_t">Pascale S, Petrucci G, Dragani A, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012; 119:3595.</a></li><li><a class="nounderline abstract_t">Michiels JJ, Berneman Z, Schroyens W, et al. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets 2006; 17:528.</a></li><li><a class="nounderline abstract_t">Tartaglia AP, Goldberg JD, Berk PD, Wasserman LR. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 1986; 23:172.</a></li><li><a class="nounderline abstract_t">Ruggeri M, Castaman G, Rodeghiero F. Is ticlopidine a safe alternative to aspirin for management of myeloproliferative disorders? Haematologica 1993; 78:18.</a></li><li><a class="nounderline abstract_t">Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350:114.</a></li><li><a class="nounderline abstract_t">Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol 1997; 56:168.</a></li><li><a class="nounderline abstract_t">Antonioli E, Guglielmelli P, Pieri L, et al. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. Am J Hematol 2012; 87:552.</a></li><li class="breakAll">Hydroxyurea capsules. United States prescribing information. Revised July 2019. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/016295s051lbl.pdf (Accessed on July 25, 2019).</li><li><a class="nounderline abstract_t">Latagliata R, Spadea A, Cedrone M, et al. Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug. Cancer 2012; 118:404.</a></li><li><a class="nounderline abstract_t">Sterkers Y, Preudhomme C, Laï JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998; 91:616.</a></li><li><a class="nounderline abstract_t">Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007; 21:270.</a></li><li><a class="nounderline abstract_t">Shibata K, Shimamoto Y, Suga K, et al. Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation--a brief review of recent literature. Acta Haematol 1994; 91:84.</a></li><li><a class="nounderline abstract_t">Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000; 110:577.</a></li><li><a class="nounderline abstract_t">Randi ML, Ruzzon E, Luzzatto G, et al. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Haematologica 2005; 90:261.</a></li><li><a class="nounderline abstract_t">Palandri F, Catani L, Testoni N, et al. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. Am J Hematol 2009; 84:215.</a></li><li><a class="nounderline abstract_t">Nand S, Stock W, Godwin J, Fisher SG. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Am J Hematol 1996; 52:42.</a></li><li><a class="nounderline abstract_t">Randi ML, Fabris F, Girolami A. Second malignancies in patients with essential thrombocythaemia. Br J Haematol 2002; 116:923.</a></li><li><a class="nounderline abstract_t">Weinfeld A, Swolin B, Westin J. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol 1994; 52:134.</a></li><li><a class="nounderline abstract_t">Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004; 117:755.</a></li><li><a class="nounderline abstract_t">Samuelsson J, Hasselbalch H, Bruserud O, et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer 2006; 106:2397.</a></li><li><a class="nounderline abstract_t">Jabbour E, Kantarjian H, Cortes J, et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer 2007; 110:2012.</a></li><li><a class="nounderline abstract_t">Gowin K, Thapaliya P, Samuelson J, et al. Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica 2012; 97:1570.</a></li><li><a class="nounderline abstract_t">Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011; 117:4706.</a></li><li><a class="nounderline abstract_t">Quintás-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009; 27:5418.</a></li><li><a class="nounderline abstract_t">Verger E, Cassinat B, Chauveau A, et al. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. Blood 2015; 126:2585.</a></li><li><a class="nounderline abstract_t">Quintás-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood 2013; 122:893.</a></li><li><a class="nounderline abstract_t">Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008; 22:1990.</a></li><li><a class="nounderline abstract_t">Taylor PC, Dolan G, Ng JP, et al. Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of published data. Br J Haematol 1996; 92:55.</a></li><li><a class="nounderline abstract_t">Quesada JR, Talpaz M, Rios A, et al. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986; 4:234.</a></li><li><a class="nounderline abstract_t">Mazur EM, Rosmarin AG, Sohl PA, et al. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 1992; 79:1931.</a></li><li><a class="nounderline abstract_t">Tomer A. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood 2002; 99:1602.</a></li><li><a class="nounderline abstract_t">Balduini CL, Bertolino G, Noris P, Ascari E. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Haematologica 1992; 77:40.</a></li><li><a class="nounderline abstract_t">Amabile CM, Spencer AP. Keeping your patient with heart failure safe: a review of potentially dangerous medications. Arch Intern Med 2004; 164:709.</a></li><li><a class="nounderline abstract_t">Jurgens DJ, Moreno-Aspitia A, Tefferi A. Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia. Haematologica 2004; 89:1394.</a></li><li><a class="nounderline abstract_t">Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group. Am J Med 1992; 92:69.</a></li><li><a class="nounderline abstract_t">Harrison CN, Mead AJ, Panchal A, et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood 2017; 130:1889.</a></li><li><a class="nounderline abstract_t">Evaluation of two antineoplastic agents, PIPOBROMAN (vercyte) and thioguanine. JAMA 1967; 200:619.</a></li><li><a class="nounderline abstract_t">Mazzucconi MG, Francesconi M, Chistolini A, et al. Pipobroman therapy of essential thrombocythemia. Scand J Haematol 1986; 37:306.</a></li><li><a class="nounderline abstract_t">De Sanctis V, Mazzucconi MG, Spadea A, et al. Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution. Br J Haematol 2003; 123:517.</a></li><li><a class="nounderline abstract_t">Passamonti F, Malabarba L, Orlandi E, et al. Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. Br J Haematol 2002; 116:855.</a></li><li><a class="nounderline abstract_t">Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood 2013; 121:4778.</a></li><li><a class="nounderline abstract_t">Barosi G, Tefferi A, Besses C, et al. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). Leukemia 2015; 29:20.</a></li><li><a class="nounderline abstract_t">Griesshammer M, Heimpel H, Pearson TC. Essential thrombocythemia and pregnancy. Leuk Lymphoma 1996; 22 Suppl 1:57.</a></li><li><a class="nounderline abstract_t">Pagliaro P, Arrigoni L, Muggiasca ML, et al. Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases. Am J Hematol 1996; 53:6.</a></li><li><a class="nounderline abstract_t">Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol 2005; 129:293.</a></li><li><a class="nounderline abstract_t">Diav-Citrin O, Hunnisett L, Sher GD, Koren G. Hydroxyurea use during pregnancy: a case report in sickle cell disease and review of the literature. Am J Hematol 1999; 60:148.</a></li><li><a class="nounderline abstract_t">Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29:761.</a></li><li><a class="nounderline abstract_t">Elliott MA, Tefferi A. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 1997; 23:463.</a></li><li><a class="nounderline abstract_t">Eliyahu S, Shalev E. Essential thrombocythemia during pregnancy. Obstet Gynecol Surv 1997; 52:243.</a></li><li><a class="nounderline abstract_t">Maze D, Kazi S, Gupta V, et al. Association of Treatments for Myeloproliferative Neoplasms During Pregnancy With Birth Rates and Maternal Outcomes: A Systematic Review and Meta-analysis. JAMA Netw Open 2019; 2:e1912666.</a></li><li><a class="nounderline abstract_t">Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131:208.</a></li><li><a class="nounderline abstract_t">Carobbio A, Finazzi G, Antonioli E, et al. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. Blood 2010; 116:1051.</a></li><li><a class="nounderline abstract_t">Montanaro M, Latagliata R, Cedrone M, et al. Thrombosis and survival in essential thrombocythemia: a regional study of 1,144 patients. Am J Hematol 2014; 89:542.</a></li></ol></div><div id="topicVersionRevision">Topic 4486 Version 62.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25037629" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21747083" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2364366" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical course of essential thrombocythemia in 147 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9631894" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cerebral vascular accidents in young patients with essential thrombocythemia: relation with other known cardiovascular risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26617062" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7700286" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35007321" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A randomized phase 3 trial of interferon-αvs hydroxyurea in polycythemia vera and essential thrombocythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16000354" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23315161" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20508163" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32266380" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17251900" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21083657" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31515250" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28794072" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23033268" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30153096" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22234683" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17127481" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3749927" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8039753" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Is ticlopidine a safe alternative to aspirin for management of myeloproliferative disorders?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14711910" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Efficacy and safety of low-dose aspirin in polycythemia vera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9371529" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Thrombotic complications in essential thrombocythemia with relatively low platelet counts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22473827" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22473827" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21692060" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9427717" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17170720" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8023650" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation--a brief review of recent literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10997967" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15710584" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19208420" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8638610" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11886403" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Second malignancies in patients with essential thrombocythaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8168592" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15541325" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16639737" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17849460" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22419578" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Experience with pegylated interferonα-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21389325" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The renaissance of interferon therapy for the treatment of myeloid malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19826111" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26486786" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical and molecular response to interferon-αtherapy in essential thrombocythemia patients with CALR mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23782935" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferonα-2a.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18843285" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8562411" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of published data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2418169" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical toxicity of interferons in cancer patients: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1562721" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11861274" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1398280" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15078640" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Keeping your patient with heart failure safe: a review of potentially dangerous medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15531464" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1731512" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29074595" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5228673" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Evaluation of two antineoplastic agents, PIPOBROMAN (vercyte) and thioguanine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3787181" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pipobroman therapy of essential thrombocythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14617017" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11886392" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23591792" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25151955" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8951773" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Essential thrombocythemia and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8813089" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15842653" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Pregnancy and its management in the Philadelphia negative myeloproliferative diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9929109" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Hydroxyurea use during pregnancy: a case report in sickle cell disease and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21205761" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9387205" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Interferon-alpha therapy in polycythemia vera and essential thrombocythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9095490" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Essential thrombocythemia during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31584685" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Association of Treatments for Myeloproliferative Neoplasms During Pregnancy With Birth Rates and Maternal Outcomes: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16197451" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20479281" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24481665" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Thrombosis and survival in essential thrombocythemia: a regional study of 1,144 patients.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
